Indoco Remedies announced final approval of the Company`s Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed drug (RLD), Vimpat Oral Solution, 10 mg/mL, of UCB, Inc. (UCB), from USFDA. Lacosamide Oral Solution USP, 10 mg/mL, is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL, of UCB, Inc. (UCB). Lacosamide Oral Solution USP, will be manufactured by Indoco Remedies, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa � 403722 in India. Lacosamide Oral solution is used to treat partial onset seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy who are at least 4 years old.Powered by Capital Market - Live News

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live News

Net Loss of Indoco Remedies reported to Rs 7.93 crore in the quarter ended September 2025 as against net loss of Rs 9.57 crore during the previous quarter ended September 2024. Sales rose 9.56% to Rs 471.83 crore in the quarter ended September 2025 as against Rs 430.66 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales471.83430.66 10 OPM %9.129.35 - PBDT19.2523.98 -20 PBT-13.00-4.84 -169 NP-7.93-9.57 17 Powered by Capital Market - Live News

Indoco Remedies will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live News

Indoco Remedies has entered into a Sale Agreement and Lease Agreement on 29 August 2025 for sale and lease back of part of the Company`s movable properties at its Waluj Facility located at B-19 MIDC, Waluj, Aurangabad, Maharashtra � 431136 (Waluj Facility) and AnaCipher Clinical Research Organisation located at 2nd, 3rd & 4th Floor, Mirrakamshetty Mall, Opp. Doordarshan Bhavan, Ramanthapur Medchal-Malkajgiri District, Hyderabad - 500013, Telangana (CRO) on the terms and conditions as mentioned therein. The sale of the aforesaid movable properties will not have any impact on the manufacturing or business of the Company, as the Company will continue to use the said movable properties on lease basis. Powered by Capital Market - Live News